Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the
treatment of hematological malignancies, but the systemic toxicity and complex …

Immunotherapy is a promising therapeutic strategy both for solid and hematologic tumors,
such as in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). In particular, immune …

Purpose The introduction of CD19-specific chimeric antigen receptor T-cell therapy (CAR-T)
for treatment of relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) gives hope to …

Novel therapeutic options have significantly improved survival and long-term outcomes in
many cancer entities. Unfortunately, this improvement in outcome is often accompanied by …

Purpose Chimeric antigen receptor (CAR) T cells have established themselves as an
effective treatment for refractory or relapsed large B cell lymphoma (LBCL). Recently, the …

The lymphatic system has grasped attention of researchers to a greater extent. The
conventional methods of lymphatic delivery are now being modified to include …

Purpose Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients
with relapsed or refractory (r/r) aggressive B-cell lymphomas. The prognosis of patients who …

Background To find semi-quantitative and quantitative Positron Emission
Tomography/Magnetic Resonance (PET/MR) imaging metrics of both tumor and non …

Simple Summary Chimeric antigen receptor–engineered T cells are an innovative therapy in
hematologic malignancies, especially in patients with refractory/relapsed B-cell lymphomas …

Chimeric antigen receptor (CAR) T-cell therapy is a cellular therapy in which the patient's T
cells are enhanced to recognize and bind to specific tumor antigens. CAR T-cell therapy was …